Prelude Capital Management’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-3,691
| Closed | -$635K | – | 2424 |
|
|
2021
Q3 | $635K | Buy |
+3,691
| New | +$483K | 0.02% | 769 |
|
|
2020
Q3 | – | Sell |
-1,696
| Closed | -$162K | – | 2555 |
|
|
2020
Q2 | $162K | Buy |
+1,696
| New | +$163K | 0.01% | 797 |
|
|
2020
Q1 | – | Sell |
-156
| Closed | -$8K | – | 2237 |
|
|
2019
Q4 | $8K | Buy |
156
+97
| +164% | +$4.42K | ﹤0.01% | 1735 |
|
|
2019
Q3 | $2K | Sell |
59
-2
| -3% | -$87 | ﹤0.01% | 1626 |
|
|
2019
Q2 | $3K | Sell |
61
-3,048
| -98% | -$126K | ﹤0.01% | 1564 |
|
|
2019
Q1 | $145K | Buy |
+3,109
| New | +$137K | 0.01% | 814 |
|
|
2018
Q4 | – | Sell |
-22,263
| Closed | -$1.27M | – | 2299 |
|
|
2018
Q3 | $1.27M | Buy |
22,263
+10,826
| +95% | +$532K | 0.07% | 305 |
|
|
2018
Q2 | $555K | Buy |
+11,437
| New | +$417K | 0.04% | 506 |
|
|
2014
Q3 | – | Sell |
-500
| Closed | -$17K | – | 2233 |
|
|
2014
Q2 | $17K | Buy |
+500
| New | +$16.7K | ﹤0.01% | 1754 |
|
Prelude Capital Management's XLRN Position: Q4 2021 in Review
Prelude Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 3,691 shares — an estimated $635K sold.
Prelude Capital Management first reported a position in XLRN in Q2 2014 and held it in 9 quarters. The position peaked at $1.27M in Q3 2018. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Prelude Capital Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Prelude Capital Management sold 3,691 Acceleron Pharma shares in Q4 2021, an estimated $635K.
- Prelude Capital Management first reported a position in Acceleron Pharma in Q2 2014 and held it in 9 quarters.
- Prelude Capital Management's Acceleron Pharma position peaked at $1.27M in Q3 2018.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Prelude Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.